Wednesday, January 10, 2007

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude Productive Year

Sales of Sepra(TM) anti-adhesion products were $23 million in the fourth quarter, 31 percent greater than $17 million in the fourth quarter a year ago. For the year, sales of Sepra products were $85 million, an increase of 25 percent compared with $68 million a year earlier.
Read Entire report
http://www.drugnewswire.com/11163/

No comments: